American Society of Hematology

Figure 2.

211At-CD38 biodistribution and pharmacokinetics. Mice bearing subcutaneous MM xenografts were IV injected with 211At-CD38 or 211At-Ab−, and ROB samples taken at 1, 25, 120, and 250 minutes posttherapy. At 24 hours posttherapy, mice were euthanized and blood, tumor, and normal tissues harvested, weighed, and γ counted, and then decay-corrected percent-injected dose of 211At absorbed per gram of tissue calculated. (A) Biodistribution of 211At-CD38. Tumors targeted by 211At-CD38 absorbed 2.4 times more activity than tumors exposed to 211At-Ab− (P = .007), and 211At-CD38 created favorable tumor-to-normal tissue ratios of absorbed activity for kidney, liver, and lungs. N = 5 mice per group; error bars = 1 SEM. (B) Blood clearance of 211At-CD38. Blood radioactivity of 211At-CD38 treated mice reduced from 60% ID per gram at 1 minute posttherapy to 38% at 2 hours and 20% at 24 hours. N = 3 mice per time point per treatment; error bars = 1 SEM.

²¹¹At-CD38 biodistribution and pharmacokinetics. Mice bearing subcutaneous MM xenografts were IV injected with ²¹¹At-CD38 or ²¹¹At-Ab⁻, and ROB samples taken at 1, 25, 120, and 250 minutes posttherapy. At 24 hours posttherapy, mice were euthanized and blood, tumor, and normal tissues harvested, weighed, and γ counted, and then decay-corrected percent-injected dose of ²¹¹At absorbed per gram of tissue calculated. (A) Biodistribution of ²¹¹At-CD38. Tumors targeted by ²¹¹At-CD38 absorbed 2.4 times more activity than tumors exposed to ²¹¹At-Ab⁻ (P = .007), and ²¹¹At-CD38 created favorable tumor-to-normal tissue ratios of absorbed activity for kidney, liver, and lungs. N = 5 mice per group; error bars = 1 SEM. (B) Blood clearance of ²¹¹At-CD38. Blood radioactivity of ²¹¹At-CD38 treated mice reduced from 60% ID per gram at 1 minute posttherapy to 38% at 2 hours and 20% at 24 hours. N = 3 mice per time point per treatment; error bars = 1 SEM.

This Feature Is Available To Subscribers Only